1688-95-5Relevant academic research and scientific papers
Triazole compounds and their use in agriculture (by machine translation)
-
Paragraph 0438; 0439; 0440, (2018/11/04)
The present invention provides a triazole compound and its application in agriculture; in particular, the invention provides compounds of formula (A) indicated by the compound and its preparation method; the composition containing these compounds and preparation and their use as fungicides; wherein R1 , R2 , R3 , W, R4 , R5 , R6 , R7 , R8 , R9 , Ra , Rb And in the event of x has the meanings given by the invention. (by machine translation)
The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors
Aoki, Toshihiro,Hyohdoh, Ikumi,Furuichi, Noriyuki,Ozawa, Sawako,Watanabe, Fumio,Matsushita, Masayuki,Sakaitani, Masahiro,Ori, Kazutomo,Takanashi, Kenji,Harada, Naoki,Tomii, Yasushi,Tabo, Mitsuyasu,Yoshinari, Kiyoshi,Aoki, Yuko,Shimma, Nobuo,Iikura, Hitoshi
supporting information, p. 6223 - 6227 (2013/11/19)
Introducing a sulfamide moiety to our coumarin derivatives afforded enhanced Raf/MEK inhibitory activity concomitantly with an acceptable PK profile. Novel sulfamide 17 showed potent HCT116 cell growth inhibition (IC 50 = 8 nM) and good PK prof
Potent and selective, sulfamide-based human β3-adrenergic receptor agonists
Dow, Robert L.,Paight, Ernest S.,Schneider, Steven R.,Hadcock, John R.,Hargrove, Diane M.,Martin, Kelly A.,Maurer, Tristan S.,Nardone, Nancy A.,Tess, David A.,DaSilva-Jardine, Paul
, p. 3235 - 3240 (2007/10/03)
A series of sulfamide-based analogs related to L-796568 were prepared and evaluated for their biological activity at the human β3- adrenergic receptor (AR). This modification allows for a significant reduction in molecular weight, while maintai
N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
-
Page 61, (2010/02/08)
Aminothiazole compounds with N-containing cycloalkyl at the 2-amino position which are represented by the Formula (I), or a pharmaceutically acceptable prodrug of said compound, or pharmaceutically acceptable salt of said compound, modulate and/or inhibit the cell proliferation and activity of protein kinases.
ENDOTHELIN CONVERTING ENZYME INHIBITORS
-
, (2008/06/13)
Compounds are disclosed which inhibit endothelin converting enzyme. These compounds are useful for treating hypertension, congestive heart failure, myocardial infarction, reperfusion injury, coronary angina, cerebral vasospasm, acute renal failure, non-steroidal antiinflammatory drug induced gastric ulceration, cyclosporin induced nephrotoxicity, endotoxin-induced toxicity, asthma and atherosclerosis.
